.Pharmacolibrary.Drugs.ATC.L.L01CA04

Information

Vinorelbine is a semi-synthetic vinca alkaloid antineoplastic agent that inhibits mitosis by binding to tubulin. It is primarily used in the treatment of non-small cell lung cancer and advanced breast cancer. Vinorelbine is approved and used in clinical oncology practice today.

Pharmacokinetics

Pharmacokinetics in adult cancer patients, after intravenous administration, based on population PK modeling.

References

1. Pétain, A, et al., & Ferré, P (2019). Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis. Cancer chemotherapy and pharmacology 84(2) 373–382. DOI:10.1007/s00280-019-03872-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31134323

2. Nguyen, L, et al., & Variol, P (2002). Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. British journal of clinical pharmacology 53(5) 459–468. DOI:10.1046/j.1365-2125.2002.01581.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/11994051

3. Variol, P, et al., & Puozzo, C (2002). A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. European journal of clinical pharmacology 58(7) 467–476. DOI:10.1007/s00228-002-0506-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12389069

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)